BNP Paribas Financial Markets’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $16.6M | Buy |
498,167
+7,384
| +2% | +$183K | 0.01% | 1337 |
|
|
2026
Q1 | $10.3M | Sell |
490,783
-412,267
| -46% | -$9.28M | 0.01% | 1549 |
|
|
2025
Q4 | $20.8M | Buy |
903,050
+330,031
| +58% | +$10.9M | 0.01% | 1154 |
|
|
2025
Q3 | $17.2M | Buy |
573,019
+347,193
| +154% | +$10.4M | 0.01% | 1195 |
|
|
2025
Q2 | $8.21M | Buy |
225,826
+48,975
| +28% | +$1.77M | ﹤0.01% | 1570 |
|
|
2025
Q1 | $6.4M | Buy |
176,851
+34,223
| +24% | +$1.42M | ﹤0.01% | 1658 |
|
|
2024
Q4 | $6M | Buy |
142,628
+113,797
| +395% | +$5.65M | ﹤0.01% | 1677 |
|
|
2024
Q3 | $1.6M | Sell |
28,831
-38,641
| -57% | -$1.97M | ﹤0.01% | 2177 |
|
|
2024
Q2 | $2.77M | Buy |
67,472
+47,579
| +239% | +$2.03M | ﹤0.01% | 1734 |
|
|
2024
Q1 | $929K | Sell |
19,893
-137,388
| -87% | -$6.48M | ﹤0.01% | 2546 |
|
|
2023
Q4 | $7.52M | Sell |
157,281
-56,994
| -27% | -$2.21M | 0.01% | 1183 |
|
|
2023
Q3 | $7.64M | Buy |
214,275
+59,312
| +38% | +$2.35M | 0.01% | 1029 |
|
|
2023
Q2 | $7.15M | Buy |
154,963
+56,435
| +57% | +$2.62M | 0.01% | 1056 |
|
|
2023
Q1 | $3.95M | Buy |
98,528
+39,104
| +66% | +$1.68M | 0.01% | 1385 |
|
|
2022
Q4 | $2.75M | Sell |
59,424
-6,573
| -10% | -$259K | ﹤0.01% | 1590 |
|
|
2022
Q3 | $2.73M | Buy |
65,997
+51,148
| +344% | +$2.63M | ﹤0.01% | 1725 |
|
|
2022
Q2 | $886K | Sell |
14,849
-2,400
| -14% | -$148K | ﹤0.01% | 2284 |
|
|
2022
Q1 | $1.25M | Sell |
17,249
-29,571
| -63% | -$2.06M | ﹤0.01% | 2160 |
|
|
2021
Q4 | $3.94M | Buy |
46,820
+36,711
| +363% | +$2.99M | 0.01% | 1514 |
|
|
2021
Q3 | $912K | Buy |
10,109
+2,673
| +36% | +$242K | ﹤0.01% | 2426 |
|
|
2021
Q2 | $709K | Sell |
7,436
-31,113
| -81% | -$3.24M | ﹤0.01% | 2369 |
|
|
2021
Q1 | $4.39M | Buy |
38,549
+20,461
| +113% | +$2.79M | 0.01% | 1238 |
|
|
2020
Q4 | $2.5M | Sell |
18,088
-16,605
| -48% | -$1.97M | ﹤0.01% | 1509 |
|
|
2020
Q3 | $2.85M | Buy |
34,693
+17,685
| +104% | +$1.47M | ﹤0.01% | 1336 |
|
|
2020
Q2 | $1.33M | Sell |
17,008
-22,824
| -57% | -$1.51M | ﹤0.01% | 1669 |
|
|
2020
Q1 | $1.77M | Buy |
39,832
+18,286
| +85% | +$949K | ﹤0.01% | 1554 |
|
|
2019
Q4 | $920K | Buy |
21,546
+788
| +4% | +$32.5K | ﹤0.01% | 2081 |
|
|
2019
Q3 | $888K | Buy |
20,758
+3,366
| +19% | +$183K | ﹤0.01% | 1909 |
|
|
2019
Q2 | $1.1M | Sell |
17,392
-7,903
| -31% | -$503K | ﹤0.01% | 1703 |
|
|
2019
Q1 | $1.75M | Buy |
25,295
+13,158
| +108% | +$752K | ﹤0.01% | 1444 |
|
|
2018
Q4 | $528K | Buy |
12,137
+534
| +5% | +$29.2K | ﹤0.01% | 1786 |
|
|
2018
Q3 | $886K | Sell |
11,603
-3,892
| -25% | -$317K | ﹤0.01% | 1797 |
|
|
2018
Q2 | $1.19M | Sell |
15,495
-8,693
| -36% | -$561K | ﹤0.01% | 1691 |
|
|
2018
Q1 | $1.23M | Buy |
24,188
+2,852
| +13% | +$144K | ﹤0.01% | 1607 |
|
|
2017
Q4 | $990K | Buy |
21,336
+6,736
| +46% | +$330K | ﹤0.01% | 1985 |
|
|
2017
Q3 | $778K | Sell |
14,600
-109
| -0.7% | -$6.46K | ﹤0.01% | 1732 |
|
|
2017
Q2 | $914K | Buy |
14,709
+5,985
| +69% | +$361K | ﹤0.01% | 1585 |
|
|
2017
Q1 | $591K | Sell |
8,724
-456
| -5% | -$34.8K | ﹤0.01% | 1645 |
|
|
2016
Q4 | $645K | Buy |
9,180
+6,186
| +207% | +$439K | ﹤0.01% | 1550 |
|
|
2016
Q3 | $212K | Sell |
2,994
-5,285
| -64% | -$337K | ﹤0.01% | 1714 |
|
|
2016
Q2 | $405K | Buy |
8,279
+8,250
| +28,448% | +$534K | ﹤0.01% | 1601 |
|
|
2016
Q1 | $1.84K | Sell |
29
-7,807
| -100% | -$511K | ﹤0.01% | 2423 |
|
|
2015
Q4 | $879K | Sell |
7,836
-25
| -0.3% | -$2.5K | ﹤0.01% | 1150 |
|
|
2015
Q3 | $757K | Buy |
7,861
+4,874
| +163% | +$558K | ﹤0.01% | 1152 |
|
|
2015
Q2 | $306K | Buy |
2,987
+2,804
| +1,532% | +$218K | ﹤0.01% | 1526 |
|
|
2015
Q1 | $11.4K | Buy |
+183
| New | +$10.2K | ﹤0.01% | 2678 |
|
|
2014
Q4 | – | Sell |
-402
| Closed | -$22.8K | – | 2925 |
|
|
2014
Q3 | $22.8K | Buy |
+402
| New | +$20.2K | ﹤0.01% | 3081 |
|
Other funds holding RARE
RI
VPM
VCM
FCM
BG
BNP Paribas Financial Markets's RARE Position: Q2 2026 in Review
BNP Paribas Financial Markets increased its Ultragenyx Pharmaceutical (RARE) stake by 1.5% in Q2 2026, buying an estimated $183K and bringing the position to 498,167 shares worth $16.6M. The position accounts for 0.01% of the portfolio, ranked #1337.
BNP Paribas Financial Markets first reported a position in RARE in Q3 2014 and has held it in 47 quarters since. The position peaked at $20.8M in Q4 2025. 250 funds tracked by Wall St. Rank hold RARE as of Q2 2026.
- BNP Paribas Financial Markets held 498,167 shares of Ultragenyx Pharmaceutical worth $16.6M as of Q2 2026.
- BNP Paribas Financial Markets bought 7,384 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $183K.
- Ultragenyx Pharmaceutical made up 0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #1337 holding.
- BNP Paribas Financial Markets first reported a position in Ultragenyx Pharmaceutical in Q3 2014 and has held it in 47 quarters since.
- BNP Paribas Financial Markets's Ultragenyx Pharmaceutical position peaked at $20.8M in Q4 2025.
- 250 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.